The detection rate of KRAS mutation in CRC samples was significantly higher than that obtained by direct sequencing; the presence of codon 12 mutation in samples undetectalbe by direct sequencing was all confirmed by clone sequencing, which demonstrated the platform’s capability to detect low-abundance mutations without influencing the accuracy. This evidence concerns the gene KRAS and colorectal carcinoma.